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The Mucopolysaccharidoses (MPS) are a group of
diseases caused by complete or partial deficiency of lyso-
somal enzymes responsible for glycosaminoglycans cata-
bolism. Their accumulation within the lysosome leads to
cellular damage and organ failure [1,2].
The musculoskeletal system is the most frequently
affected one. Joint stiffness, contractures (claw hand),
dysostosis multiplex, and carpal tunnel syndrome are
some of the most frequent features [3-9]. Often the
joint symptoms may be confused with inflammatory
arthritides such as Juvenile Idiopathic Arthritis [10,11].
A prompt differential diagnoses is a fundamental step:
in MPS patients there are no signs of local inflammation
such as swelling, warmth and tenderness, and lack of
fever and increased inflammatory markers. In addition,
patients with MPS do not respond to anti-rheumatic
therapy [12,13].
In addition, characteristic facies, cognitive impairment,
short stature, recurrent otitis media, sleep apnea, hear-
ing, vision and heart problems can be present [14,15].
Because of a wide variety of clinical presentation, diag-
nosis of MPS disorders is often delayed, especially in
patients with mild forms and without neurocognitive
impairment such as Scheie Syndrome.
When clinical features are suggestive for MPS, the diag-
nosis is confirmed with the assay of urinary GAG con-
centration, which is a sensitive but not specific method
[16] and, as the gold standard with determination of the
specific enzyme in cultured fibroblasts, leukocytes, plasma
or serum [17]. The genetic sequencing could be used to
identify the disease-causing mutation.
The managment of MPS disorders requires a multidis-
ciplinary evaluation for multi-organ involvement. The
new therapeutic approaches to MPS have drastically
changed the natural history of disease. Transplantation
of hematopoietic stem cells from bone marrow or umbi-
lical cord can achieve significant benefits. The clinical
success of this therapeutic approach depends on age,
stage of disease, type of donor and ability to achieve
stable engraftment without the development of graft-vs-
host disease [18,20]. In early stages of disease, enzyme
replacement therapy can benefit musculoskeletal symp-
toms and lung function [21-23]. This therapy, however,
does not cross the blood-brain barrier and has not
shown neurocognitive benefit.
In conclusion, the goal is the prompt identification of
MPS disorders since an early diagnosis could allow early
treatment: in this regard, particular attention should be
given to an accurate differential diagnosis with chronic
inflammatory arthropathies.
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